Toripalimab, an emerging cancer therapy developed by Zhangjiang’s Junshi Biosciences, is applied in treatment at the Beijing Cancer Hospital for the first time on Feb 26. [Photo/pdtimes.com.cn]
Shanghai has been continuously introducing relevant policies in the pharmaceutical industry in recent years, creating many opportunities for its biomedical innovation enterprises.
The in-depth promotion of some pilot programs, the marketing authorization holder (MAH) system and the medical device registration system, for example, have accelerated the industrialization of homegrown innovative drugs, and helped the local enterprises seize market opportunities.
The Zhangjiang National Innovation Demonstration Zone, also known as Zhangjiang Pharma Valley, is a manufacturing base of biological medicine for Shanghai and an industry leader in China.
According to Lou Qi, general manager of Shanghai Zhangjiang Biotech & Pharmaceutical Base Development Co Ltd, the enterprises in Zhangjiang cover many forward-looking fields, including tumor immunotherapy, cell therapy, gene therapy and next-generation sequencing.
Zai Lab, a company in Zhangjiang, announces the listing of its product, Optune, in Hong Kong for the treatment of glioblastoma multiforme (GBM) on Feb 28. [Photo/WeChat account: zjpark]
Toripalimab, an emerging cancer therapy that boosts the immune system to help the body to target and kill tumors, developed by Zhangjiang's Junshi Biosciences, is the first self-developed anti-PD-1 treatment in China.
It was used in treatment at the Beijing Cancer Hospital for the first time on Feb 26, and will soon be available in 51 cities nationwide.
Another Zhangjiang company, Zai Lab, announced the listing of its product, Optune, in Hong Kong for the treatment of glioblastoma multiforme (GBM) on Feb 28.
The first and only tumor electric field treatment product approved by the US Food and Drug Administration (FDA), Optune has also been approved for GBM treatment in Europe, Japan and many other countries and regions.
The rapid development of Zhangjiang's pharmaceutical industry has drawn the attention of many global leading venture capital companies. The continuous financing is promoting R&D of new drugs by Zhangjiang's innovative pharmaceutical enterprises.
Additionally, with the Shanghai Center for Drug Safety Evaluation and Research and the Zhangjiang Cross-border Scientific Innovation Supervision Service Center being settled in Zhangjiang, relevant enterprises have easy access to all-round services.
No comments:
Post a Comment